Report #2835095

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: Mar 25, 2025
Onset: Mar 25, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
TDAP	TDAP (BOOSTRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	L5229	—

Symptoms (1)

Exposure during pregnancy

Symptom narrative

Drug exposure during pregnancy; This non-serious prospective pregnancy case was reported by a nurse via registry and described the occurrence of vaccine exposure during pregnancy in a 32-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number L5229, expiry date 19-APR-2027) for prophylaxis. On 25-MAR-2025, the patient received the 1st dose of Boostrix. On 25-MAR-2025, an unknown time after receiving Boostrix, the patient experienced vaccine exposure during pregnancy (Verbatim: Drug exposure during pregnancy). The outcome of the vaccine exposure during pregnancy was not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 27-MAR-2025 Other HCP stated that pregnant woman received Boostrix which led to vaccine exposure during pregnancy.